Axitinib Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 1 mg, 5 mg

Reference Brands: Inlyta®(EU & US)

Category: Oncology Cancer Care

Axitinib 1 mg and 5 mg Tablets are used in oncology for the treatment of metastatic renal cell carcinoma (RCC). Available under the brand name Inlyta®, Axitinib is a tyrosine kinase inhibitor that targets VEGF receptors to inhibit tumor growth. It is used as a second-line therapy after the failure of prior treatments like sunitinib or pazopanib. Available in oral tablet form, it is typically taken twice daily. Axitinib is available in Tablets and strengths such as 1 mg, 5 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Axitinib is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Axitinib can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description: Axitinib 1 mg and 5 mg Tablets are a key treatment for metastatic renal cell carcinoma (RCC), primarily used as a second-line therapy for patients who have failed prior treatments like sunitinib or pazopanib. As a tyrosine kinase inhibitor, Axitinib targets the VEGF receptors involved in tumor angiogenesis, thus slowing the growth of cancer cells. Approved under the brand name Inlyta® in both the U.S. and EU, Axitinib is essential in oncology B2B portfolios for advanced RCC treatment. It is typically administered twice daily in oral tablet form at doses of 1 mg or 5 mg.